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Abstract. A lifestyle rich in physical and mental activities protects against Alzheimer’s disease (AD) but the underlying
mechanisms are unclear. We have proposed that this is mediated by a stress response and have shown that repeated exposure to
novelty stress, which induces physical and exploratory activities, delays the progression of AD-like pathology in the TASTPM
mouse model. Here, we aimed to establish the role played by corticotrophin-releasing factor receptor 1 (CRFR1), a major
component of the stress axis, in TASTPM’s behavioral and neuroendocrine responses to novelty and related protective effects.
We show that the stress response of TASTPM mice is altered with reduced CRFR1-mediated neuroendocrine and behavioral
responses to novelty and a distinct profile of behavioral responses. Repeated novelty-induced CRFR1 activation, however,
mediated the improved contextual fear memory and extinction performance of TASTPM mice and increased hippocampal and
fronto-cortical levels of synaptophysin, a marker of synaptic density, and fronto-cortical levels of the post-synaptic marker
PSD95. The N-methyl-D-aspartate receptor (NMDAR) is the major receptor for synaptic plasticity underlying learning and
memory. Although novelty-induced NMDAR activation contributed to enhancement of fear memory and synaptophysin levels,
antagonism of CRFR1 and NMDAR prevented the novelty-induced increase in hippocampal synaptophysin levels but reversed
the other effects of CRFR1 inactivation, i.e., the enhancement of contextual fear extinction and fronto-cortical synaptophysin and
PSD95 levels. These findings suggest a novel mechanism whereby a stimulating environment can delay AD symptoms through
CRFR1 activation, facilitating NMDAR-mediated synaptic plasticity and synaptogenesis in a region-dependent manner, either
directly, or indirectly, by modulating PSD95.
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INTRODUCTION
A number of studies have established that a lifestyle
rich in physical and mental exercise decreases the risk
and progression of Alzheimer’s disease (AD) [1–3]
but the underlying mechanisms are yet to be fully
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understood. Susceptibility to stress is a risk factor for
AD but positive lifestyle factors effective in delaying
AD progression in mouse models (e.g., exercise,
environmental enrichment) improve stress resistance
despite inducing a number of markers of chronic stress,
such as a sustained activation of the hypothalamic-
pituitary-adrenal (HPA) axis [1, 4]. This led us to the
hypothesis that the protective effect on AD progression
is mediated, at least in part, by a stress response.
In support of this hypothesis, we have shown that
repeated exposure to novelty stress, induced by the
placement of mice in a novel clean cage for repeated
1-hour sessions, induces HPA axis activation and
locomotor and exploratory activities, which do not
habituate with repeated exposure [5], while delaying
the progression of contextual fear memory deficits
and amyloid load in a genetic mouse model of AD
(TASTPM mouse line) [4, 6]. Using this procedure
and a pharmacological approach, we aimed to estab-
lish a role for corticotrophin-releasing factor receptor 1
(CRFR1) signaling in the cognitive benefits of novelty
sessions in TASTPM mice.
Corticotrophin-releasing factor (CRF) is a major
contributor to the stress response and is widely dis-
tributed within the central nervous system, including
key areas affected by AD (e.g., hippocampus, cortex,
and hypothalamus). CRF binds to two major recep-
tors, CRFR1 and CRFR2, to mediate its effects, but
CRFR1 is the most critical for stress responses and
AD. In the hypothalamus, CRF controls the HPA stress
response and subsequent release of glucocorticoids via
CRFR1 [7]. CRF is also synthesized locally in response
to stress in which it stimulates excitatory neurotrans-
mission also via CRFR1, thereby mediating a range of
functions necessary for adaptation [8] and relevant to
AD, such as cognition, neuroprotection, neuroinflam-
mation, amyloid, and tau processing [9]. Postmortem
observation of AD brains has revealed altered CRF
and CRFR1 levels in the hypothalamus and other brain
areas [9], together with increased circulating levels of
glucocorticoids [10].
We therefore hypothesized that CRFR1 signal-
ing would be reduced in TASTPM mice at a
pre-pathological age contributing to altered stress-
responses and disease progression. Accordingly, we
characterized the behavioral and neuroendocrine
responses to acute novelty stress and antagonism of the
two CRF receptors, CRFR1 and CRFR2, in wild-type
(WT) and TASTPM mice aged 4 months, when cog-
nitive deficits and amyloid pathology are subtle [4].
We found that CRFR1-mediated effects are reduced
in TASTPM mice and tested the hypothesis that this
deficit would be rescued by repeated novelty sessions,
contributing to the cognition-enhancing effects. The
loss of synapses is the major correlate of cognitive
decline in AD [11] and CRF, via CRFR1, modu-
lates hippocampal synaptic function and plasticity and,
thereby, learning and memory [12]. We, therefore,
quantified hippocampal and fronto-cortical levels of
the presynaptic protein synaptophysin and postsynap-
tic marker postsynaptic density protein 95 (PSD95).
CRF modulates excitatory glutamatergic transmission
in a CRF receptor-dependent manner [13] and the glu-
tamatergic ionotropic N-methyl-D-aspartate receptor
(NMDAR) is the major receptor for synaptic plas-
ticity underlying learning and memory [14]. This
prompted us to test the hypothesis that interactions
between the two receptors contribute to the cognition-
enhancing effects of repeated novelty. We found
that, although CRFR1 signaling is reduced in pre-
pathological TASTPM mice, its repeated activation
mediates the cognitive and synaptic benefits of novelty
sessions, but not via co-activation of NMDAR, except
for enhancement of hippocampal synaptogenesis.
MATERIAL AND METHODS
Animals
TASTPM transgenic mice and wild type C57BL/6J
control mice were generated and maintained as pre-
viously described [4, 6, 15,]. All procedures were
undertaken in accordance with the UK animals Sci-
entific Procedures Act under project license 40/2715.
Study design
Three experiments were performed. First, 4-month-
old WT and TASTPM mice were either undisturbed or
subjected to an acute novelty session (n = 15/group). At
the end of the 1-h session, trunk blood was collected
for determination of plasma adrenocorticotropic hor-
mone (ACTH) and corticosterone levels, their brain
was collected, and the hippocampi and frontal cor-
tices dissected on ice for assessment of glutamate
levels (n = 7/group) using high performance liquid
chromatography or protein levels of the presynaptic
marker synaptophysin and postsynaptic marker PSD95
(n = 8/group) using western immunoblotting. This age
is characterized by minor plaque pathology and subtle
cognitive deficits [4, 16].
Because TASTPM mice differed from WT mice
in their HPA response to novelty, and CRF recep-
tors modulate HPA axis and behavioral reactivity
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to stress, the effects of antagonism of CRFR1 or
CRFR2 on neuroendocrine, physiological, and behav-
ioral responses to novelty stress were investigated
(n = 7–9 per genotype and treatment condition). The
number of fecal pellets and novelty-induced behav-
iors (rearing, leaning, grooming, and tail rattling) were
recorded manually by an observer blind to the experi-
mental groups as described previously [5].
Because TASTPM mice showed altered CRFR1-
mediated responses to novelty and because CRFR1
influences synaptic plasticity underlying learning and
memory while and NMDAR is the major receptor for
synaptic plasticity, we tested the hypothesis that both
receptors interact to produce the cognition-enhancing
effects of repeated exposure to novelty in TASTPM
mice. Antagonists of CRFR1 and/or NMDAR were
administered i.p. 30 min prior to each novelty ses-
sion. After 5 weeks of exposure, mice were tested for
locomotor, anxiety-related, and cognitive performance
using the open-field and contextual fear conditioning
test (n = 10–13/group). 72 h after the last behavioral
test, mice were killed by decapitation. Trunk blood was
collected for assessment of plasma levels of ACTH
and corticosterone, and their brain was removed and
dissected for assessment of hippocampal and fronto-
cortical levels of synaptophysin and PSD95. Because
repeated injections are stressful, the impact of repeated
injections was also tested in TASTPM and WT mice
(8–10/group).
Novelty stress
The procedure was carried out as described previ-
ously [4, 17] either once for 1 h or 4 times 1 h/day for 5
weeks, by placing the mouse into a clean cage, devoid
of food, water, or environmental enrichment and
bisected by a Perspex partition in order to restrict the
space available by half. Unexposed mice were handled.
Drug treatments
Because available CRF2 antagonists do not cross
the blood-brain barrier, in the acute study, the CRFR1
antagonist CP154,526 (7 nmol; Tocris), CRFR2 antag-
onist anti-sauvagine (100 pmol; Bachem), or vehicle
(saline) were administered i.c.v. by direct infusion into
the right ventricle (4l for 5 min, stereotaxic coor-
dinates: AP −0.3 mm; ML +1 mm and DV −2.0 mm;
relative to bregma) under isofluorane anesthesia. The
injector was then left in place for 1 min, the incision
was closed and the mouse left to recover for 30 min,
prior to being subjected to the acute novelty session
and then, culled immediately for collection of trunk
blood and verification of the injection site.
For the repeated exposure to novelty, the CRFR1
antagonist CP154,526 (10 mg/kg), NMDAR antag-
onist MK801 (0.1 mg/kg), or vehicle (saline 5%
Tween-20) were administered i.p. 30 min before each
session. The effect of a CRFR2 antagonist could not
be tested due to animal welfare concerns, as it would
require 20 i.c.v. injections under brief anesthesia.
Behavioral assessment
Locomotion in the open field test as well as
acquisition, retention, and extinction of contextual
fear conditioning were performed and analyzed as
described previously [4, 18].
The open-field comprised a Perspex arena
(30 × 35 × 25 cm) with transparent sides and a grey
floor and behavior was recorded by a camera positioned
directly above the arena. Locomotor activity (distance
travelled) was automatically assessed using Ethovison
Software (Noldus, Wageningen, Netherlands).
The shock chamber (25 × 25 × 38 cm) used for con-
textual fear conditioning comprised three stainless
steel walls and one transparent Perspex wall. The floor
consisted of stainless steel bars 1 cm apart that were
connected to a shock generator (Campden Instruments,
Loughborough, UK).
During the acquisition trial, mice received one
0.4 mA foot shock each minute for 10 min with the
first shock given after 60 s, resulting in a total of 10
shocks throughout the trial. A retention trial took place
24 h later in which the mice were placed back into the
shock chamber for 3 min in the absence of shocks. 24 h
after the retention trial, the mice were placed back
in the chamber for a 3-min extinction trial, again in
the absence of shocks. Again, activity was recorded
and subsequently analyzed by an observer blind to
genotype or treatment. Behavior was recorded by a
camera positioned directly above the arena for subse-
quent analysis. Learning and memory were assessed by
recording immobility levels during each trial. Immo-
bility levels were scored by two observers blind to the
experimental groups and averaged for statistical anal-
yses. When the two values differed by more than 10 s,
the scoring was repeated and the two closest values
used for analysis.
Plasma hormone levels
Trunk blood was separated as described previously
[4]. Corticosterone and ACTH levels were assessed
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in duplicate using ELISAs (Stressgen and Phoenix
Experimental, respectively) according to manufac-
turer’s instructions.
Western immunoblotting
Tissue was lysed as described previously [19].
Lysates were normalized for total protein con-
centration using the BCA protein assay (Pierce).
Proteins were resolved by SDS-polyacrylamide gel
electrophoresis on 10% gels and transferred to nitro-
cellulose membranes (Amersham Biosciences). The
membranes were probed with primary antibodies
against GAPDH (1/20000, Sigma), PSD95 (1/12500,
Sigma), and synaptophysin (1/15000, Sigma), blocked
with 3% fish skin gelatin and then probed with IRDye
800CW goat anti-mouse, IRDye 680CW goat anti-
rabbit secondary antibodies (LI-COR Biosciences).
Blotted proteins were detected and quantified using
the Odyssey infrared imaging system (LI-COR).
Statistical analyses
Data were analyzed using the InVivoStat soft-
ware [20]. One-way analyses of variance (ANOVAs),
two-way ANOVAs, and repeated measure ANOVAs,
were followed by post-hoc planned comparisons when
appropriate using Fisher PLSD test. p < 0.05 was con-
sidered significant.
RESULTS
TASTPM mice show altered behavioral and HPA
responses to novelty stress
We first quantified the acute novelty-induced rise
in stress hormone levels in 4-month-old WT and
TASTPM mice. The ACTH response of TASTPM
mice was reduced but the corticosterone response was
unaltered, despite elevated baseline plasma corticos-
terone levels (Supplementary Figure 1A, B; available
online: http://www.j-alz.com/issues/34/vol34-3.html
#supplementarydata04). A blunted ACTH response
associated with unaltered corticosterone response has
also been seen in mild to moderate AD patients sub-
jected to a CRF challenge [21], suggesting that CRF
signaling is altered in pre-pathological TASTPM mice.
We, therefore, investigated whether antagonism of
CRFR1, using CP154,526, or CRFR2, using anti-
sauvagine, altered neuroendocrine, physiological, and
behavioral responses to acute novelty.
Novelty-induced ACTH release was attenuated by
pre-treatment with either CRFR1 or CRFR2 antag-
onists in WT mice (p = 0.02, p = 0.14, and p = 0.24
versus undisturbed levels, respectively, Fig. 1A).
TASTPM’ ACTH levels were unaltered by nov-
elty exposure and CRFR1 or CRFR2 antagonism
(p = 0.94, p = 0.93, and p = 0.33 versus unexposed lev-
els, respectively, Fig. 1A) but their basal (p < 0.001)
and novelty-induced (p = 0.009) circulating corticos-
terone levels were higher than those of WT mice
(Fig. 1B). Novelty induced corticosterone release in
both WT (p < 0.001) and TASTPM (p = 0.005) mice,
which was unaltered by CRFR1 or CRFR2 blockade in
either genotype (all p < 0.001 versus unexposed levels,
Fig. 1B).
WT and TASTPM mice also differed markedly in
their behavioral responses to novelty with TASTPM
mice exhibiting less wall-leaning (F(1,39) = 87.03;
p < 0.001, Fig. 1C), rearing (F(1,39) = 24.77; p < 0.001,
Fig. 1D), and grooming (F(1,39) = 6.95; p = 0.01,
Fig. 1E) behaviors, but more tail rattling (F(1,39) =
27.16; p < 0.001, Supplementary Figure 2A). CRFR1
antagonism significantly increased novelty-induced
leaning (p = 0.004) and rearing (p = 0.02) behaviors in
WT, but not TASTPM mice (p = 0.74 and p = 0.99,
respectively), consistent with reported anxiogenic
effects of central CRFR1 activation [22]. CRFR2
antagonism failed to alter the behavioral responses
of WT mice, but normalized grooming activity in
TASTPM mice (p = 0.63 versus vehicle-treated WT,
Fig. 1E). Thus, CRFR1 signaling is apparently reduced
in TASTPM mice contributing to some aspects of their
modified stress responses. CRFR1 is the main CRF
receptor in the hippocampus and frontal cortex [23],
two brain regions involved in contextual fear memory
and extinction. We therefore investigated its involve-
ment, via interactions with NMDAR, in the cognitive
benefits of repeated novelty in TASTPM mice. The dif-
ferent stress responses of WT and TASTPM mice also
prompted us to test the impact of repeated injection
stress. Since this procedure produced adverse effects
in WT but not TASTPM mice (detailed below), only
TASTPM mice were used for the chronic pharmaco-
logical study.
After 5 weeks of novelty sessions, baseline corti-
costerone levels were no longer elevated in TASTPM
mice and baseline ACTH levels did not differ, irrespec-
tive of the injection status (Supplementary Table 1),
indicating that the early hypercorticolism of TASTPM
mice was rescued by handling and exposing the mice
to the novel cage. Antagonism of novelty-induced
CRFR1 and/or NMDAR activation, using CP154,526
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Fig. 1. Reduced CRFR1 signaling in TASTPM mice. WT and TASTPM mice were exposed to novelty for 1-hour, 30 minutes after receiving
an i.c.v. injection of saline, CRFR1 or CRFR2 antagonists (7 nmol CP154,526 and 100 pmol anti-sauvagine, respectively). Novelty increased
plasma ACTH levels in WT but not in TASTPM mice nor following CRFR1 and CRFR2 antagonism (A). TASTPM had increased baseline
and novelty-induced levels of corticosterone, unaltered by CRFR1 or CRFR2 antagonism in either genotype (B). Blockade of novelty-induced
CRFR1 activation increased wall-leaning (C) and rearing (D) behaviors in WT but not TASTPM mice, while CRFR2 blockade rescued novelty-
induced grooming levels in TASTPM mice (E). ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 versus undisturbed (same genotype). +p < 0.05, ++p < 0.01,
+++p < 0.001.
and MK801, respectively, did not alter baseline ACTH
and corticosterone levels (Supplementary Table 2).
Defecations induced by acute novelty exposure were
not altered in TASTPM mice or by prior antagonism
of CRFR1 or CRFR2 in either genotype (Supple-
mentary Figure 2B). Defecations induced by repeated
novelty sessions in TASTPM mice were decreased
by blocking CRFR1 activation and increased by
blocking NMDAR activation (p = 0.03 and p = 0.003
versus vehicle-treated TASTPM), an effect attenu-
ated by co-treatment with CP154,526 (p = 0.16 versus
vehicle-treated TASTPM, Supplementary Figure 2C,
Treatment: F(3,40) = 10.48; p < 0.001). This is unlikely
due to altered food intake as none of the drugs altered
body weights (Supplementary Table 2). Thus, CRFR1
and NMDAR mediate opposing effects on physiolog-
ical responses to novelty in TASTPM mice.
In summary, the altered stress responses of TASTPM
mice were characterized by a reduced ACTH secre-
tion and reduced vertical activity and self-grooming
behavior as well as increased tail-rattling. The failure
of CRFR1 antagonism to reduce the novelty-induced
ACTH secretion and to increase vertical activity of
TASTPM mice suggests that CRFR1 signaling is
impaired in these mice contributing to their altered
stress responsiveness.
CRFR1 activation contributes to the cognitive
beneﬁts of novelty exposure independently of
NMDAR activation
Distances traveled in the open-field were unaltered
by any of the experimental conditions (Supplementary
Tables 1 and 2) indicating that differences in locomotor
activity did not confound contextual fear conditioning,
as assessed by immobility levels.
All experimental groups similarly acquired contex-
tual fear (Fig. 2A, B). Contextual fear memory was
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Fig. 2. CRFR1 signaling mediates novelty-induced cognitive improvement in TASTPM mice. After 20 novelty exposures combined with vehicle,
CRFR1 and/or NMDAR antagonism (10 mg/kg CP154,526 and/or 0.1 mg/kg MK801, i.p.), mice were subjected to 10 context-footshock pairings.
All groups similarly acquired contextual fear (A& B) but fear memory was reduced in TASTPM mice and by the injection stress in WT but
not TASTPM mice (C). Novelty exposures enhanced fear memory of TASTPM mice through CRFR1 and NMDAR activation independently of
each other (D). Contextual fear extinction was impaired in TASTPM mice (E) and this was rescued by novelty-induced CRFR1 activation (F).
∗p < 0.05, ∗∗p < 0.01 versus undisturbed vehicle-treated. #p < 0.05, ##p < 0.01 versus 0 (lack ofextinction). ++p < 0.01.
lower in TASTPM mice (F(1,31) = 5.26; p = 0.03) and
was reduced to TASTPM levels in vehicle-injected
WT mice (p = 0.32 versus vehicle-treated TASTPM,
Fig. 2C). Exposures to novelty enhanced fear memory
of TASTPM mice (p = 0.03 versus unexposed vehicle-
treated), an effect prevented by CP154,526 and MK801
treatments (p = 0.32 and p = 0.09 versus unexposed
vehicle-treated, respectively, Fig. 2D) suggesting that
both CRFR1 and NMDAR activation contributed to
the memory improvement, but independently, as a
combination of antagonists did not prevent the memory
enhancement (p = 0.004 versus unexposed vehicle-
treated, Treatment: F(4,47) = 2.63; p = 0.04, Fig. 2D).
Contextual fear extinction was reduced in TASTPM
mice (Genotype: F(1,31) = 14.16; p < 0.001) and,
whereas WT mice showed significant memory
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Fig. 3. CRFR1 signaling mediates the synaptogenic effects of novelty exposures. Hippocampal synaptophysin levels were unaltered in TASTPM
mice (A) but were increased by repeated exposure to novelty via co-activation of CRFR1 and NMDAR (B). Fronto-cortical synaptophysin levels
were reduced by repeated injections (C) but increased by novelty-induced CRFR1 and NMDAR activation independently of each other (D).
Representative western blots (E). ∗p < 0.05, ∗∗p < 0.01 versus undisturbed vehicle-treated. #p < 0.05.
extinction (non-injected p = 0.015 and vehicle-treated
p = 0.017 versus 0, i.e., lack of extinction), TASTPM
did not (non-injected p = 0.86 and vehicle-treated
p = 0.48 versus 0, Fig. 2E). The extinction deficit was
rescued by repeated novelty sessions (p = 0.005 ver-
sus 0), an effect prevented by antagonism of CRFR1
but not NMDAR alone or in combination with CRFR1
blockade (p = 0.29, p = 0.002 and p = 0.014 versus 0,
respectively, Fig. 2F).Thus, novelty-induced CRFR1
activation contributes to the memory improvement but
not by directly activating NMDAR.
In summary, despite altered stress responses,
TASTPM mice were resistant to the memory deficits
caused by the stress of i.p. injections in WT mice.
The repeated exposure of TASTPM mice to a novel
environment increased contextual fear memory per-
formance and reversed their deficit in contextual fear
memory extinction via CRFR1 activation.
CRFR1 activation mediates novelty-induced
increase in synaptic density region-dependently
via NMDAR activation
Synaptophysin levels of WT and TASTPM mice
did not differ in the hippocampus (F(1,32) = 2.12;
p = 0.15, Fig. 3A) and frontal cortex (F(1,32) = 0.49;
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p = 0.49, Fig. 3C) and were unaltered by an
acute novelty session (Supplementary Figure 1C,
D). Repeated injections reduced fronto-cortical
(F(1,32) = 4.17; p = 0.05, Fig. 3C) but not hippocam-
pal (F(1,32) = 0.39; p = 0.54, Fig. 3A) synaptophysin
levels in both genotypes. Repeated novelty sessions
increased synaptophysin levels of TASTPM mice in
both brain regions (p = 0.003 and p = 0.01 versus unex-
posed vehicle-treated for hippocampus and frontal
cortex, respectively, Fig. 3B, D) via activation of
CRFR1 and NMDAR (CP154,526 versus unexposed
vehicle-treated p = 0.13 and p = 0.33; MK801 versus
unexposed vehicle-treated p = 0.51 and p = 0.41 for
hippocampus and frontal cortex, respectively, Fig. 3B,
D). Antagonism of novelty-induced both CRFR1 and
NMDAR activation prevented the rise in hippocampal
but not fronto-cortical synaptophysin levels (p = 0.50
and p = 0.01 versus unexposed vehicle-treated, Fig. 3B,
D). Thus, activation of both receptors is required for
controlling synaptic density.
In contrast, PSD95 levels of TASTPM mice were
reduced in the hippocampus (Supplementary Figure 1E
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Table 1
Summary of findings
Findings in TASTPM mice Figure/Table
HPA axis activity Blunted ACTH stress response Fig. 1A, Supp. Fig. 1A
CRFR1 antagonism failed to reduce ACTH secretion Fig. 1A
Elevated baseline corticosterone levels Fig. 1B, Supp. Fig. 1B
Behavioral stress response Reduced vertical activity and self-grooming behavior Fig. 1C–E
Increased tail rattling behavior Supp. Fig. 2A
CRFR1 antagonism failed to increase vertical activity Fig. 1C, D
CRFR2 antagonism restored self-grooming activity Fig. 1E
Stress-induced defecations Unaltered by acute novelty and CRFR1 or CRFR2
antagonism
Supp. Fig. 1B
Reduced by repeated CRFR1 antagonism and increased
by repeated NMDAR antagonism
Supp. Fig. 1C
Locomotor activity Unaltered by any treatment conditions Supp. Tables 1 and 2
Acquisition of contextual fear memory Unaltered by any treatment conditions Fig. 2A, B
Contextual fear memory Unaltered by the stress of repeated i.p. injections Fig. 2C
Improved by the repeated exposure to novelty via
CRFR1 activation
Fig. 2D
Contextual fear extinction Impaired in TASTPM mice Fig. 2E
Rescued by the repeated exposure to novelty via CRFR1
activation
Fig. 2F
Synaptophysin levels Increased by the repeated exposure to novelty in both
the hippocampus and frontal cortex via CRFR1 and
NMDAR activation
Fig. 3B, D
PSD95 levels Reduced hippocampal levels rescued by the stress of
repeated i.p. injections
Fig. 4A, Supp. Fig. 1E
Increased in the frontal cortex by the repeated exposure
to novelty via CRFR1 activation
Fig. 4D
and p < 0.001 versus non-injected WT, Fig. 4A) but not
frontal cortex (Supplementary Figure 1F and p = 0.30
versus non-injected WT, Fig. 4C), and unaltered by
acute novelty (Supplementary Figure 1E, F). Repeated
injections reduced hippocampal PSD95 levels of WT
mice (p = 0.004 versus non-injected, Fig. 4A) but
increased those of TASTPM mice (p = 0.002 versus
non-injected, Fig. 4A) thereby returning them to con-
trol levels (p = 0.44 versus non-injected WT, Fig. 4A).
Neither repeated novelty, nor any of the drugs, altered
hippocampal PSD95 levels (group: F(4,47) = 0.44;
p = 0.78, Fig. 4B). Fronto-cortical PSD95 levels of
TASTPM mice were increased by repeated novelty
sessions (p = 0.007 versus unexposed vehicle-treated,
Fig. 4D) via CRFR1 (p = 0.94 versus unexposed
vehicle-treated, Fig. 4D) but not NMDAR activa-
tion as MK801 did not prevent this increase, either
when administered alone or in combination with
CP154,526 (p = 0.02 versus unexposed vehicle-treated
in both cases, Fig. 4D). Thus, CRFR1 signaling dur-
ing repeated exposures to novelty region-dependently
modulates PSD95 levels.
In summary, at the age of 4 months, TASTPM mice
exhibited reduced hippocampal levels of PSD95 and
this was rescued by the repeated stress of injection.
Repeated exposure to novelty stress enhanced synapto-
physin levels in the hippocampus and frontal cortex of
TASTPM mice via activation of CRFR1 and NMDAR.
Moreover, the increased in fronto-cortical PSD95
levels in TASTPM mice was mediated by activation
of CRFR1 but not NMDAR.
DISCUSSION
The work reported here aimed to establish that a
stimulating environment improved AD-like pathology
by inducing a stress response and the key findings
are summarized in Table 1. We established here that
CRFR1 signaling, a major regulator of neuroendocrine
and behavioral stress responses, mediates the protec-
tive effects of a stimulating environment in TASTPM
mice. We first showed that stress responses to a sin-
gle exposure to a novel environment were altered in
pre-pathological TASTPM mice with reduced CRFR1-
mediated effects, although they were resistant to the
adverse cognitive and synaptic effects of repeated
injection stress seen in WT mice. In contrast, repeated
CRFR1 activation during the novelty sessions con-
tributed to the improved contextual fear memory and
extinction, and associated synaptogenesis, seen in
TASTPM mice, indicating that the deficient CRFR1
responses were rescued by a stimulating environment,
contributing to cognitive improvement. Although
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NMDAR activation critically modulates synaptic plas-
ticity thought to underlie learning and memory [14],
antagonism of novelty-induced NMDAR activation
mimicked some of the effects of CRFR1 antagonism,
but reversed rather than amplified its fronto-cortical
cognitive and synaptic effects.
CRFR1 signaling is impaired in early AD-like
pathology in TASTPM mice, a mechanism for
stress susceptibility?
Despite epidemiological evidence linking pre-
morbid stress susceptibility with an enhanced risk of
AD [24], this has not been investigated in detail in
mouse models. A prolonged corticosterone response to
restraint stress, but unaltered baseline or stress-induced
levels of the hormone have been reported in young
APP-overexpressing mice [25] while 3xTg AD mice,
with mutated APP, PS1, and tau genes, have ele-
vated baseline and stress-induced corticosterone levels
[26]. The baseline hypercorticolism of asymptomatic
TASTPM mice was associated with a blunted ACTH
but an unaltered corticosterone response to acute nov-
elty, and with a very distinct pattern of behavioral
responses. A similar neuroendocrine profile has been
observed in AD patients subjected to a CRF challenge
[21], suggesting reduced CRF signaling. The failure of
TASTPM mice to exhibit the behavioral and neuroen-
docrine effects of blockade of novelty-induced CRFR1
or CRFR2 activation further confirms this hypothesis.
Whether this is a mechanism for stress susceptibil-
ity is unclear, as TASTPM mice were resistant to
the adverse effects of repeated injection stress seen
in WT mice. Injections induce a short-lasting corti-
costerone response [27], and thus, the altered HPA
response of TASTPM mice may confer some protec-
tion against adverse effects of mild stressors. Indeed,
the blunted ACTH stress response may prevent fur-
ther HPA axis activation, consistent with the lack of
differences between WT and TASTPM mice for stress
levels of corticosterone, although later time points need
to be investigated to confirm this hypothesis. Such
stress resistance, however, is unlikely to protect against
intense stressors since repeated restraint stress [28] and
chronic mild stress [29] exacerbate AD-like pathology.
CRFR1 signaling contributes to AD progression
We found that CRFR1 activation mediates the
enhanced cognitive performance and synaptogenesis
of TASTPM mice exposed to a stimulating envi-
ronment, which is consistent with the hypothesis
that reduced CRFR1 signaling contributes to human
AD progression [9]. Moreover, social isolation stress
upregulated hippocampal and cortical CRFR1 levels
of APP overexpressing mice [30], despite unaltered
extracellular CRF levels [31], suggesting that chronic
stress reduces CRFR1 signaling, thereby contribut-
ing to exacerbated AD-like pathology. Furthermore,
CRF, via CRFR1, was found to protect cortical and
hippocampal neurons from amyloid--induced death
in vitro [32]. In contrast, increased CRF function
was found to contribute to restraint stress-induced
amyloid- release [31] and exacerbation of plaque
load [28] in APP and APP/PS1 overexpressing
mice, respectively, whereas APP transgenic mice
overexpressing CRF displayed exacerbated cognitive
and amyloid pathology [33]. This further supports
a role for CRF in AD progression, although the
receptor(s) mediating these effects need to be estab-
lished. CRF dose-dependently increases amyloid-
release [31], leading to the hypothesis that it pro-
duces positive or negative effects on AD progression
as function of the severity of the stressors, although a
CRF receptor-dependency cannot be excluded. Indeed,
CRFR2, but not CRFR1 deletion, was found to mediate
stress-induced tau phosphorylation in wild-type mice
[34]. Moreover, CRFR2 antagonism rescued novelty-
induced grooming levels in TASTPM mice suggesting
that its altered function also contributes to AD progres-
sion. The lack of a selective CRFR2 antagonist that
crosses the blood-brain barrier, however, prevented us
from testing its involvement in the protective effects of
repeated novelty.
Synaptogenesis contributes to novelty-induced
cognitive improvement in a CRFR1- and
NMDAR-dependent manner
CRF, via CRFR1, modulates hippocampal synaptic
function and plasticity and, thereby, learning and mem-
ory, in a time- and dose-dependent manner, with short
exposure to stress levels promoting positive effects but
long exposure promoting synapse loss and cognitive
impairments [12]. Thus, the blockade of novelty-
induced increases in synaptophysin levels by CRFR1
antagonism suggests that the improved contextual
fear memory and extinction, which require hippocam-
pal and fronto-cortical integrity, are mediated by an
increase in synaptic density resulting from repeated,
intermittent CRF secretion. Our data also suggest that
NMDAR activation region-dependently contributes
to the synaptogenic and cognition-enhancing effects
of novelty sessions. In support of this hypothesis,
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NMDAR activation was found to alter synaptogenesis
in vitro, in a time-dependent manner, promoting it in
the short-term and reducing it as a result of chronic
activation [35]. In vivo, pre-treatment with MK801
was found to prevent water-maze overtraining-induced
synaptogenesis in the adult hippocampus and impaired
memory performance [36] while, in a genetic model of
NMDAR hypofunction, memory deficits and reduced
fronto-cortical dendritic spine density were observed
[37]. Co-antagonism of CRFR1 and NMDAR, how-
ever, prevented the rise in hippocampal, but not
fronto-cortical, synaptophysin levels, suggesting that
the two receptors stimulate each other in the former, but
not latter, brain area to induce protective effects. This
is consistent with the reported region-dependent mod-
ulation of glutamatergic transmission by CRF, which,
via CRFR1, was found to depress glutamatergic trans-
mission in the central nucleus of the amygdala, while
facilitating it in the lateral septum mediolateral nucleus
[13], hippocampus and basolateral amygdala [22]. In
rat fronto-cortical slices, however, CRF was found
to inhibit glutamatergic synaptic transmission in a
NMDAR-dependent manner [38]. Thus, the enhanced
fronto-cortical synaptic density and extinction of con-
textual fear following blockade of novelty-induced
both CRFR1 and NMDAR activation likely reflects
synergistic facilitatory effects on synaptic glutamater-
gic transmission. Altogether, this suggests that CRFR1
activation protects against AD-related impairment
by inducing synaptogenesis through directly enhanc-
ing hippocampal, but not fronto-cortical NMDAR
function.
Novelty-induced CRFR1 activation enhances
fronto-cortical PSD95 levels
PSD95 is an activity-dependent regulator of
NMDAR and synaptic plasticity and is thought to act
as a sensor regulating MMDAR function in response
to alterations in synaptic activity [39]. Our results,
showing that hippocampal PSD95 levels are reduced
in 4-month-old TASTPM mice, suggest that functional
synaptic plasticity of the hippocampus is impaired
prior to the onset of behavioral symptoms. This reduc-
tion in PSD95 levels was still evident at 5.5 months,
once contextual fear memory was impaired. The injec-
tion stress reversed the reduced hippocampal PSD95
levels of TASTPM mice but not the memory deficits
while decreasing memory performance and hippocam-
pal PSD95 levels of WT mice, suggesting that other
molecular mechanisms also contribute to AD-related
cognitive symptoms. PSD95 levels are closely linked
Fig. 5. Hypothetical mechanism underling protective effects of pos-
itive lifestyle factors on the progression of Alzheimer’s disease (AD)
cognitive decline. The deficient CRFR1 signaling at the onset of cog-
nitive symptoms would be rescued by an active lifestyle resulting in
enhanced cognitive function through directly increasing NMDAR-
mediated synaptic plasticity and synaptogenesis in the hippocampus,
and indirectly in the frontal cortex via accumulation of PSD95.
to the function of glutamatergic receptors, potentiat-
ing activation of NMDAR through direct and indirect
interactions. PSD95 accumulation accelerates the mat-
uration of excitatory synapses [40], increases NMDAR
protein levels [39] and reduces NMDAR desensiti-
zation [41]. Thus, we hypothesize that the reduced
hippocampal PSD95 levels of young TASTPM mice
associated with unaltered glutamate levels (Supple-
mentary Figure 1G) reflect NMDAR hypofunction,
the rescue of which by repeated injections enabled
the beneficial effects of CRFR1 activation on hip-
pocampal synaptogenesis and function. In the frontal
cortex, the enhanced PSD95 level was prevented by
blockade of novelty-induced CRFR1 activation. This
suggests that CRFR1 indirectly stimulates NMDAR
function through an increase in PSD95 levels possibly
occurring to compensate for CRF-induced depression
of synaptic glutamatergic transmission. The failure of
792 G.A. Scullion et al. / CRFR1 Signalling Protects Against Early Cognitive Decline in AβPP/PS1 Mice
the combination of antagonists to prevent the novelty-
induced increase in fronto-cortical PSD95 levels,
would therefore be the consequence of the antago-
nistic effects of CRFR1 and NMDAR activation, the
former directly inhibiting and the latter stimulating
synaptic glutamatergic transmission. Further studies
are, however, needed to verify this hypothesis. Our
data also further support the observation that genet-
ically induced NMDAR hypofunction does not alter
PSD95 levels in the mouse hippocampus or frontal cor-
tex [42], but to the best of our knowledge, this is the first
evidence that CRFR1 activation increases PSD95 lev-
els. This may be a mechanism whereby CRF indirectly
potentiates NMDAR-related synaptic plasticity and
synaptogenesis.
CONCLUSIONS
The data presented in this paper suggest a novel
mechanism whereby a stimulating environment can
delay the progression of AD-like symptoms and
reverse the pre-morbid stress susceptibility contribut-
ing to the disease. Accordingly, the intermittent
secretion of CRF via CRFR1 facilitates NMDAR-
mediated synaptic plasticity and synaptogenesis which
are critical for learning and memory performance
either directly or indirectly by promoting accumulation
of PSD95 (Fig. 5).
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